161 related articles for article (PubMed ID: 11341669)
21. A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease.
Hongo M; Kinoshita Y; Haruma K
J Gastroenterol; 2008; 43(6):448-56. PubMed ID: 18600389
[TBL] [Abstract][Full Text] [Related]
22. On-demand treatment of acute heartburn with the antacid hydrotalcite compared with famotidine and placebo: randomized double-blind cross-over study.
Holtmeier W; Holtmann G; Caspary WF; Weingärtner U
J Clin Gastroenterol; 2007 Jul; 41(6):564-70. PubMed ID: 17577112
[TBL] [Abstract][Full Text] [Related]
23. Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer.
Hu FL; Jia JC; Li YL; Yang GB
J Int Med Res; 2003; 31(6):469-74. PubMed ID: 14708410
[TBL] [Abstract][Full Text] [Related]
24. Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitis.
Simon TJ; Roberts WG; Berlin RG; Hayden LJ; Berman RS; Reagan JE
Clin Ther; 1995; 17(6):1147-56. PubMed ID: 8750406
[TBL] [Abstract][Full Text] [Related]
25. A double-blind randomized study of cisapride in the treatment of nonulcer dyspepsia. The Canadian Cisapride Nud Study Group.
Champion MC; MacCannell KL; Thomson AB; Tanton R; Eberhard S; Sullivan SN; Archambault A
Can J Gastroenterol; 1997 Mar; 11(2):127-34. PubMed ID: 9113812
[TBL] [Abstract][Full Text] [Related]
26. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori.
Borody TJ; Andrews P; Fracchia G; Brandl S; Shortis NP; Bae H
Gut; 1995 Oct; 37(4):477-81. PubMed ID: 7489931
[TBL] [Abstract][Full Text] [Related]
27. Famotidine (MK-208) in the treatment of gastric ulcer. Results of a multicenter double-blind controlled study.
Paoluzi P; Torsoli A; Bianchi Porro G; Lazzaroni M; Barbara L; Corinaldesi R; Blasi A; Mangiameli A; Carratelli L; Cheli R
Digestion; 1985; 32 Suppl 1():38-44. PubMed ID: 2866135
[TBL] [Abstract][Full Text] [Related]
28. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Ng FH; Wong SY; Lam KF; Chu WM; Chan P; Ling YH; Kng C; Yuen WC; Lau YK; Kwan A; Wong BC
Gastroenterology; 2010 Jan; 138(1):82-8. PubMed ID: 19837071
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: is camostat mesilate effective?
Ashizawa N; Hashimoto T; Miyake T; Shizuku T; Imaoka T; Kinoshita Y
J Gastroenterol Hepatol; 2006 Apr; 21(4):767-71. PubMed ID: 16677167
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.
Poynard T; Lemaire M; Agostini H
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):661-5. PubMed ID: 8590162
[TBL] [Abstract][Full Text] [Related]
31. Famotidine to prevent peptic ulcer caused by NSAIDs.
Graham DY
N Engl J Med; 1996 Oct; 335(17):1322; author reply 1322-3. PubMed ID: 8992333
[No Abstract] [Full Text] [Related]
32. Ranitidine effectively relieves symptoms in a subset of patients with functional dyspepsia.
Farup PG; Wetterhus S; Osnes M; Ulshagen K
Scand J Gastroenterol; 1997 Aug; 32(8):755-9. PubMed ID: 9282965
[TBL] [Abstract][Full Text] [Related]
33. [Clinical aspects of Kvamatel (famotidine) administration].
Golochevskaia VS
Klin Med (Mosk); 1996; 74(1):45-7. PubMed ID: 8649009
[No Abstract] [Full Text] [Related]
34. Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data.
Deutsch SI; Rosse RB; Kendrick KA; Fay-McCarthy M; Collins JP; Wyatt RJ
Clin Neuropharmacol; 1993 Dec; 16(6):518-24. PubMed ID: 9377587
[TBL] [Abstract][Full Text] [Related]
35. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial.
Kantorova I; Svoboda P; Scheer P; Doubek J; Rehorkova D; Bosakova H; Ochmann J
Hepatogastroenterology; 2004; 51(57):757-61. PubMed ID: 15143910
[TBL] [Abstract][Full Text] [Related]
36. Famotidine in the treatment of acute urticaria.
Watson NT; Weiss EL; Harter PM
Clin Exp Dermatol; 2000 May; 25(3):186-9. PubMed ID: 10844490
[TBL] [Abstract][Full Text] [Related]
37. Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine.
Miyake K; Ueki N; Suzuki K; Shinji Y; Kusunoki M; Hiratsuka T; Nishigaki H; Tatsuguchi A; Futagami S; Wada K; Tsukui T; Nakajima A; Yoshino S; Sakamoto C
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():67-72. PubMed ID: 15943850
[TBL] [Abstract][Full Text] [Related]
38. A multicenter, double-blind, randomized, placebo-controlled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease.
Gitlin N; McCullough AJ; Smith JL; Mantell G; Berman R
Gastroenterology; 1987 Jan; 92(1):48-53. PubMed ID: 2877912
[TBL] [Abstract][Full Text] [Related]
39. H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials.
Redstone HA; Barrowman N; Veldhuyzen Van Zanten SJ
Aliment Pharmacol Ther; 2001 Sep; 15(9):1291-9. PubMed ID: 11552898
[TBL] [Abstract][Full Text] [Related]
40. Famotidine to prevent peptic ulcer caused by NSAIDs.
Singh G; Fries JF
N Engl J Med; 1996 Oct; 335(17):1322; author reply 1322-3. PubMed ID: 8992334
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
